Adenylyl cyclase activating polypeptide reduces phosphorylation and toxicity of the polyglutamine-expanded androgen receptor in spinobulbar muscular atrophy

Science Translational Medicine

Volumn 8, Issue 370, 2016, Pages

  Polanco, Maria Josè ^a,b   Parodi, Sara ^b,c   Piol, Diana ^a   Stack, Conor ^c   Chivet, Mathilde ^a   Contestabile, Andrea ^b   Miranda, Helen C ^d   Lievens, Patricia M J ^e   Espinoza, Stefano ^b   Jochum, Tobias ^f   Rocchi, Anna ^b   Grunseich, Christopher ^c   Gainetdinov, Raul R ^g,h   Cato, Andrew C B ⁱ   Lieberman, Andrew P ^j   La Spada, Albert R ^d   Sambataro, Fabio ^k   Fischbeck, Kenneth H ^c   Gozes, Illana ^l   Pennuto, Maria ^a,b  

^a UNIVERSITY OF TRENTO   (Italy)

^b ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF VERONA   (Italy)

^f KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^g ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

^h SKOLKOVO INSTITUTE OF SCIENCE AND TECHNOLOGY   (Russian Federation)

ⁱ KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

^j UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^k UNIVERSITY OF UDINE   (Italy)

^l TEL AVIV UNIVERSITY   (Israel)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ANDROGEN RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 2; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; POLYGLUTAMINE; SERINE; CDK2 PROTEIN, HUMAN; CDK2 PROTEIN, MOUSE; GLUTAMINE; LIGAND; PEPTIDE;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KENNEDY DISEASE; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEUROMODULATION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; RAT; SIGNAL TRANSDUCTION; ANIMAL; CELL PROLIFERATION; CHEMISTRY; HEK293 CELL LINE; METABOLISM; MUSCLE ATROPHY; PC12 CELL LINE; PHOSPHORYLATION; PROTEIN DENATURATION; PROTEIN FOLDING; SPRAGUE DAWLEY RAT; TRANSGENIC MOUSE;

ANIMALS; CELL PROLIFERATION; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIN-DEPENDENT KINASE 2; GLUTAMINE; HEK293 CELLS; HUMANS; LIGANDS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, TRANSGENIC; MUSCULAR DISORDERS, ATROPHIC; PC12 CELLS; PEPTIDES; PHOSPHORYLATION; PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE; PROTEIN DENATURATION; PROTEIN FOLDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 85007018158     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aaf9526     Document Type: Article

References (72)

1. A. R. La Spada, E. M. Wilson, D. B. Lubahn, A. E. Harding, K. H. Fischbeck, Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352, 77-79 (1991).
2. W. R. Kennedy, M. Alter, J. H. Sung, Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 18, 671-680 (1968).
3. H. T. Orr, H. Y. Zoghbi, Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575-621 (2007).
4. H. B. Kordasiewicz, L. M. Stanek, E. V. Wancewicz, C. Mazur, M. M. McAlonis, K. A. Pytel, J. W. Artates, A. Weiss, S. H. Cheng, L. S. Shihabuddin, G. Hung, C. F. Bennett, D. W. Cleveland, Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74, 1031-1044 (2012).
5. N. Pourshafie, P. R. Lee, K.-l. Chen, G. G. Harmison, L. C. Bott, M. Katsuno, G. Sobue, B. G. Burnett, K. H. Fischbeck, C. Rinaldi, MiR-298 counteracts mutant androgen receptor toxicity in spinal and bulbar muscular atrophy. Mol. Ther. 24, 937-945 (2016).
6. A. P. Lieberman, Z. Yu, S. Murray, R. Peralta, A. Low, S. Guo, X. X. Yu, C. J. Cortes, C. F. Bennett, B. P. Monia, A. R. La Spada, G. Hung, Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 7, 774-784 (2014).
7. I. Palazzolo, B. G. Burnett, J. E. Young, P. L. Brenne, A. R. La Spada, K. H. Fischbeck, B. W. Howell, M. Pennuto, Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Hum. Mol. Genet. 16, 1593-1603 (2007).
8. I. Palazzolo, C. Stack, L. Kong, A. Musaro, H. Adachi, M. Katsuno, G. Sobue, J. P. Taylor, C. J. Sumner, K. H. Fischbeck, M. Pennuto, Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63, 316-328 (2009).
9. L. E. Fernández-Rhodes, A. D. Kokkinis, M. J. White, C. A. Watts, S. Auh, N. O. Jeffries, J. A. Shrader, T. J. Lehky, L. Li, J. E. Ryder, E. W. Levy, B. I. Solomon, M. O. Harris-Love, A. La Pean, A. B. Schindler, C. Chen, N. A. Di Prospero, K. H. Fischbeck, Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: A randomised placebo-controlled trial. Lancet Neurol. 10, 140-147 (2011).
10. M. Katsuno, H. Banno, K. Suzuki, Y. Takeuchi, M. Kawashima, I. Yabe, H. Sasaki, M. Aoki, M. Morita, I. Nakano, K. Kanai, S. Ito, K. Ishikawa, H. Mizusawa, T. Yamamoto, S. Tsuji, K. Hasegawa, T. Shimohata, M. Nishizawa, H. Miyajima, F. Kanda, Y. Watanabe, K. Nakashima, A. Tsujino, T. Yamashita, M. Uchino, Y. Fujimoto, F. Tanaka, G. Sobue; Japan SBMA Interventional Trial for TAP-144-SR (JASMITT) study group, Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 875-884 (2010).
11. M. Katsuno, H. Adachi, A. Kume, M. Li, Y. Nakagomi, H. Niwa, C. Sang, Y. Kobayashi, M. Doyu, G. Sobue, Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 35, 843-854 (2002).
12. C. Scaramuzzino, I. Casci, S. Parodi, P. M. J. Lievens, M. J. Polanco, C. Milioto, M. Chivet, J. Monaghan, A. Mishra, N. Badders, T. Aggarwal, C. Grunseich, F. Sambataro, M. Basso, F. O. Fackelmayer, J. P. Taylor, U. B. Pandey, M. Pennuto, Protein arginine methyltransferase 6 enhances polyglutamine-expanded androgen receptor function and toxicity in spinal and bulbar muscular atrophy. Neuron 85, 88-100 (2015).
13. D. Gioeli, S. B. Ficarro, J. J. Kwiek, D. Aaronson, M. Hancock, A. D. Catling, F. M. White, R. E. Christian, R. E. Settlage, J. Shabanowitz, D. F. Hunt, M. J. Weber, Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem. 277, 29304-29314 (2002).
14. G. Jenster, P. E. de Ruiter, H. A. van der Korput, G. G. Kuiper, J. Trapman, A. O. Brinkmann, Changes in the abundance of androgen receptor isotypes: Effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry 33, 14064-14072 (1994).
15. H. Y. Wong, J. A. Burghoorn, M. van Leeuwen, P. E. de Ruiter, E. Schippers, L. J. Blok, K. W. Li, H. L. Dekker, L. de Jong, J. Trapman, J. A. Grootegoed, A. O. Brinkmann, Phosphorylation of androgen receptor isoforms. Biochem. J. 383, 267-276 (2004).
16. A. Errico, K. Deshmukh, Y. Tanaka, A. Pozniakovsky, T. Hunt, Identification of substrates for cyclin dependent kinases. Adv. Enzyme Regul. 50, 375-399 (2010).
17. Y. Koryakina, H. Q. Ta, D. Gioeli, Androgen receptor phosphorylation: Biological context and functional consequences. Endocr. Relat. Cancer 21, T131-T145 (2014).
18. L. J. Blok, P. E. de Ruiter, A. O. Brinkmann, Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding. Biochemistry 37, 3850-3857 (1998).
19. M. Pennuto, M. Basso, In vitro and in vivo modeling of spinal and bulbar muscular atrophy. J. Mol. Neurosci. 58, 365-373 (2015).
20. D. Reglodi, P. Kiss, A. Lubics, A. Tamas, Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr. Pharm. Des. 17, 962-972 (2011).
21. D. Vaudry, A. Falluel-Morel, S. Bourgault, M. Basille, D. Burel, O. Wurtz, A. Fournier, B. K. C. Chow, H. Hashimoto, L. Galas, H. Vaudry, Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 61, 283-357 (2009).
22. L. S. Barak, A. Salahpour, X. Zhang, B. Masri, T. D. Sotnikova, A. J. Ramsey, J. D. Violin, R. J. Lefkowitz, M. G. Caron, R. R. Gainetdinov, Pharmacological characterization of membrane-expressed human trace amine-associated receptor 1 (TAAR1) by a bioluminescence resonance energy transfer cAMP biosensor. Mol. Pharmacol. 74, 585-594 (2008).
23. S. Chen, Y. Xu, X. Yuan, G. J. Bubley, S. P. Balk, Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc. Natl. Acad. Sci. U.S.A. 103, 15969-15974 (2006).
24. F.-N. Hsu, M.-C. Chen, M.-C. Chiang, E. Lin, Y.-T. Lee, P.-H. Huang, G.-S. Lee, H. Lin, Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J. Biol. Chem. 286, 33141-33149 (2011).
25. D. J. Messner, P. Ao, A. B. Jagdale, A. L. Boynton, Abbreviated cell cycle progression induced by the serine/threonine protein phosphatase inhibitor okadaic acid at concentrations that promote neoplastic transformation. Carcinogenesis 22, 1163-1172 (2001).
26. M. Kõivomägi, E. Valk, R. Venta, A. Iofik, M. Lepiku, E. R. Balog, S. M. Rubin, D. O. Morgan, M. Loog, Cascades of multisite phosphorylation control Sic1 destruction at the onset of S phase. Nature 480, 128-131 (2011).
27. L. Zboray, A. Pluciennik, D. Curtis, Y. Liu, L. D. Berman-Booty, C. Orr, C. T. Kesler, T. Berger, D. Gioeli, B. M. Paschal, D. E. Merry, Preventing the androgen receptor N/C interaction delays disease onset in a mouse model of SBMA. Cell Rep. 13, 2312-2323 (2015).
28. T. Jochum, M. E. Ritz, C. Schuster, S. F. Funderburk, K. Jehle, K. Schmitz, F. Brinkmann, M. Hirtz, D. Moss, A. C. B. Cato, Toxic and non-toxic aggregates from the SBMA and normal forms of androgen receptor have distinct oligomeric structures. Biochim. Biophys. Acta 1822, 1070-1078 (2012).
29. N.-D. Doan, S. Bourgault, A. Dejda, M. Létourneau, M. Detheux, D. Vaudry, H. Vaudry, D. Chatenet, A. Fournier, Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects. Biochem. Pharmacol. 81, 552-561 (2011).
30. S. Bourgault, D. Vaudry, B. Botia, A. Couvineau, M. Laburthe, H. Vaudry, A. Fournier, Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides 29, 919-932 (2008).
31. E. H. Lee, S. R. Seo, Neuroprotective roles of pituitary adenylate cyclase-activating polypeptide in neurodegenerative diseases. BMB Rep. 47, 369-375 (2014).
32. Z. Yu, N. Dadgar, M. Albertelli, A. Scheller, R. L. Albin, D. M. Robins, A. P. Lieberman, Abnormalities of germ cell maturation and Sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. Am. J. Pathol. 168, 195-204 (2006).
33. A. Rocchi, C. Milioto, S. Parodi, A. Armirotti, D. Borgia, M. Pellegrini, A. Urciuolo, S. Molon, V. Morbidoni, M. Marabita, V. Romanello, P. Gatto, B. Blaauw, P. Bonaldo, F. Sambataro, D. M. Robins, A. P. Lieberman, G. Soraru, L. Vergani, M. Sandri, M. Pennuto, Glycolytic-to-oxidative fiber-type switch and mTOR signaling activation are early-onset features of SBMA muscle modified by high-fat diet. Acta Neuropathol. 132, 127-144 (2016).
34. S.-O. Lee, S. Chintharlapalli, S. Liu, S. Papineni, S. D. Cho, K. Yoon, S. Safe, p21 expression is induced by activation of nuclear nerve growth factor-induced Ba (Nur77) in pancreatic cancer cells. Mol. Cancer Res. 7, 1169-1178 (2009).
35. B. Y. Lam, W. Zhang, D. C.-H. Ng, M. Maruthappu, H. L. Roderick, S. Chawla, CREBdependent Nur77 induction following depolarization in PC12 cells and neurons is modulated by MEF2 transcription factors. J. Neurochem. 112, 1065-1073 (2010).
36. E. Giorgetti, Z. Yu, J. P. Chua, R. Shimamura, L. Zhao, F. Zhu, S. Venneti, M. Pennuto, Y. Guan, G. Hung, A. P. Lieberman, Rescue of metabolic alterations in AR113Q skeletal muscle by peripheral androgen receptor gene silencing. Cell Rep. 17, 125-136 (2016).
37. C. J. Cortes, H. C. Miranda, H. Frankowski, Y. Batlevi, J. E. Young, A. Le, N. Ivanov, B. L. Sopher, C. Carromeu, A. R. Muotri, G. A. Garden, A. R. La Spada, Polyglutamineexpanded androgen receptor interferes with TFEB to elicit autophagy defects in SBMA. Nat. Neurosci. 17, 1180-1189 (2014).
38. Z. X. Zhou, J. A. Kemppainen, E. M. Wilson, Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol. Endocrinol. 9, 605-615 (1995).
39. Z. Zhu, R. R. Becklin, D. M. Desiderio, J. T. Dalton, Identification of a novel phosphorylation site in human androgen receptor by mass spectrometry. Biochem. Biophys. Res. Commun. 284, 836-844 (2001).
40. J. Lindqvist, S. Y. Imanishi, E. Torvaldson, M. Malinen, M. Remes, F. Örn, J. J. Palvimo, J. E. Eriksson, Cyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cells. Mol. Biol. Cell 26, 1971-1984 (2015).
41. D. Gioeli, B. E. Black, V. Gordon, A. Spencer, C. T. Kesler, S. T. Eblen, B. M. Paschal, M. J. Weber, Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization. Mol. Endocrinol. 20, 503-515 (2006).
42. I. K. Mellinghoff, I. Vivanco, A. Kwon, C. Tran, J. Wongvipat, C. L. Sawyers, HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6, 517-527 (2004).
43. C. T. Kesler, D. Gioeli, M. R. Conaway, M. J. Weber, B. M. Paschal, Subcellular localization modulates activation function 1 domain phosphorylation in the androgen receptor. Mol. Endocrinol. 21, 2071-2084 (2007).
44. K. Baumann, E.-M. Mandelkow, J. Biernat, H. Piwnica-Worms, E. Mandelkow, Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 336, 417-424 (1993).
45. D. Moujalled, J. L. James, S. Yang, K. Zhang, C. Duncan, D. M. Moujalled, S. J. Parker, A. Caragounis, G. Lidgerwood, B. J. Turner, J. D. Atkin, A. Grubman, J. R. Liddell, C. Proepper, T. M. Boeckers, K. M. Kanninen, I. Blair, P. J. Crouch, A. R. White, Phosphorylation of hnRNP K by cyclin-dependent kinase 2 controls cytosolic accumulation of TDP-43. Hum. Mol. Genet. 24, 1655-1669 (2015).
46. M. Asada, T. Yamada, H. Ichijo, D. Delia, K. Miyazono, K. Fukumuro, S. Mizutani, Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation. EMBO J. 18, 1223-1234 (1999).
47. Z. Nagy, The dysregulation of the cell cycle and the diagnosis of Alzheimer's disease. Biochim. Biophys. Acta 1772, 402-408 (2007).
48. P. Delobel, I. Lavenir, B. Ghetti, M. Holzer, M. Goedert, Cell-cycle markers in a transgenic mouse model of human tauopathy: Increased levels of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1. Am. J. Pathol. 168, 878-887 (2006).
49. S. Humbert, E. A. Bryson, F. P. Cordelières, N. C. Connors, S. R. Datta, S. Finkbeiner, M. E. Greenberg, F. Saudou, The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2, 831-837 (2002).
50. N. D. Jorgensen, J. M. Andresen, S. Lagalwar, B. Armstrong, S. Stevens, C. E. Byam, L. A. Duvick, S. Lai, P. Jafar-Nejad, H. Y. Zoghbi, H. B. Clark, H. T. Orr, Phosphorylation of ATXN1 at Ser776 in the cerebellum. J. Neurochem. 110, 675-686 (2009).
51. D. Rat, U. Schmitt, F. Tippmann, I. Dewachter, C. Theunis, E. Wieczerzak, R. Postina, F. van Leuven, F. Fahrenholz, E. Kojro, Neuropeptide pituitary adenylate cyclaseactivating polypeptide (PACAP) slows down Alzheimer's disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 3208-3218 (2011).
52. D. Reglodi, A. Lubics, A. Tamás, L. Szalontay, I. Lengvári, Pituitary adenylate cyclase activating polypeptide protects dopaminergic neurons and improves behavioral deficits in a rat model of Parkinson's disease. Behav. Brain Res. 151, 303-312 (2004).
53. A. Tamás, A. Lubics, I. Lengvári, D. Reglódi, Protective effects of PACAP in excitotoxic striatal lesion. Ann. N. Y. Acad. Sci. 1070, 570-574 (2006).
54. K. J. Ressler, K. B. Mercer, B. Bradley, T. Jovanovic, A. Mahan, K. Kerley, S. D. Norrholm, V. Kilaru, A. K. Smith, A. J. Myers, M. Ramirez, A. Engel, S. E. Hammack, D. Toufexis, K. M. Braas, E. B. Binder, V. May, Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470, 492-497 (2011).
55. J. Born, T. Lange, W. Kern, G. P. McGregor, U. Bickel, H. L. Fehm, Sniffing neuropeptides: A transnasal approach to the human brain. Nat. Neurosci. 5, 514-516 (2002).
56. D. Doberer, M. Gschwandtner, W. Mosgoeller, C. Bieglmayer, H. Heinzl, V. Petkov, Pulmonary and systemic effects of inhaled PACAP38 in healthy male subjects. Eur. J. Clin. Invest. 37, 665-672 (2007).
57. F. Sambataro, M. Pennuto, Cell-autonomous and non-cell-autonomous toxicity in polyglutamine diseases. Prog. Neurobiol. 97, 152-172 (2012).
58. M. J. Pérez-García, S. J. Burden, Increasing MuSK activity delays denervation and improves motor function in ALS mice. Cell Rep. 2, 497-502 (2012).
59. J. L. Walcott, D. E. Merry, Ligand promotes intranuclear inclusions in a novel cell model of spinal and bulbar muscular atrophy. J. Biol. Chem. 277, 50855-50859 (2002).
60. M. De Palma, L. Naldini, Transduction of a gene expression cassette using advanced generation lentiviral vectors. Methods Enzymol. 346, 514-529 (2002).
61. G. Bony, J. Szczurkowska, I. Tamagno, M. Shelly, A. Contestabile, L. Cancedda, Nonhyperpolarizing GABAB receptor activation regulates neuronal migration and neurite growth and specification by cAMP/LKB1. Nat. Commun. 4, 1800 (2013).
62. D. Pozzi, G. Lignani, E. Ferrea, A. Contestabile, F. Paonessa, R. D'Alessandro, P. Lippiello, D. Boido, A. Fassio, J. Meldolesi, F. Valtorta, F. Benfenati, P. Baldelli, REST/NRSF-mediated intrinsic homeostasis protects neuronal networks from hyperexitability. EMBO J. 32, 2994-3007 (2013).
63. C. Grunseich, K. Zukosky, I. R. Kats, L. Ghosh, G. G. Harmison, L. C. Bott, C. Rinaldi, K.-l. Chen, G. Chen, M. Boehm, K. H. Fischbeck, Stem cell-derived motor neurons from spinal and bulbar muscular atrophy patients. Neurobiol. Dis. 70, 12-20 (2014).
64. I. Gozes, O. Perl, E. Giladi, A. Davidson, O. Ashur-Fabian, S. Rubinraut, M. Fridkin, Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: Neuroprotective drug design. Proc. Natl. Acad. Sci. U.S.A. 96, 4143-4148 (1999).
65. I. Gozes, A. Bardea, A. Reshef, R. Zamostiano, S. Zhukovsky, S. Rubinraut, M. Fridkin, D. E. Brenneman, Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide. Proc. Natl. Acad. Sci. U.S.A. 93, 427-432 (1996).
66. I. Gozes, G. Lilling, R. Glazer, A. Ticher, I. E. Ashkenazi, A. Davidson, S. Rubinraut, M. Fridkin, D. E. Brenneman, Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J. Pharmacol. Exp. Ther. 273, 161-167 (1995).
67. S. Espinoza, A. Salahpour, B. Masri, T. D. Sotnikova, M. Messa, L. S. Barak, M. G. Caron, R. R. Gainetdinov, Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol. Pharmacol. 80, 416-425 (2011).
68. A. Salahpour, S. Espinoza, B. Masri, V. Lam, L. S. Barak, R. R. Gainetdinov, BRET biosensors to study GPCR biology, pharmacology, and signal transduction. Front. Endocrinol. 3 (2012)
69. T. Jochum, A. C. Cato, Analysis of the conformation of the androgen receptor in spinal bulbar muscular atrophy by atomic force microscopy. Methods Mol. Biol. 1204, 197-204 (2014).
70. Z. Yu, N. Dadgar, M. Albertelli, K. Gruis, C. Jordan, D. M. Robins, A. P. Lieberman, Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. J. Clin. Invest. 116, 2663-2672 (2006).
71. M. A. Albertelli, A. Scheller, M. Brogley, D. M. Robins, Replacing the mouse androgen receptor with human alleles demonstrates glutamine tract length-dependent effects on physiology and tumorigenesis in mice. Mol. Endocrinol. 20, 1248-1260 (2006).
72. R. N. Alcalay, E. Giladi, C. G. Pick, I. Gozes, Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci. Lett. 361, 128-131 (2004).